» Articles » PMID: 36061732

Inhibition Of Tau Protein Aggregation By a Chaperone-like β-Boswellic Acid Conjugated To Gold Nanoparticles

Overview
Journal ACS Omega
Specialty Chemistry
Date 2022 Sep 5
PMID 36061732
Authors
Affiliations
Soon will be listed here.
Abstract

A potential therapeutic strategy to inhibit tau protein aggregation in neurons has substantial effects on preventing or controlling Alzheimer's disease (AD). In this work, we designed a covalent and noncovalent conjugation of β-boswellic acid (BA) to gold nanoparticles (GNPs). We provided the opportunity to investigate the effect of the surface composition of BA-GNPs on the aggregation of the tau protein 1N/4R isoform in vitro. HR-TEM and FESEM micrographs revealed that GNPs were spherical and uniform, smaller than 25 nm. According to UV-visible and FTIR data, BA was successfully conjugated to GNPs. The finding illustrates the effect of the surface charge, size, and hydrophobicity of BA-GNPs on the kinetics of tau protein aggregation. The size and surface area of U-G-BA demonstrated that inhibited tau aggregation more effectively than covalently linked BA. The proposed method for preventing tau aggregation was monomer reduction. At the same time, a chaperone-like feature of GNP-BA while sustaining a tau native structure prevented the additional formation of fibrils. Overall, this study provides insight into the interaction of GNP-BAs with a monomer of tau protein and may suggest novel future therapies for AD.

Citing Articles

Design and Development of Natural-Product-Derived Nanoassemblies and Their Interactions with Alpha Synuclein.

Banerjee I, Das A, Biggs M, Phan C, Cutter L, Ren A Biomimetics (Basel). 2025; 10(2).

PMID: 39997105 PMC: 11852371. DOI: 10.3390/biomimetics10020082.


Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions.

Paul P, Rathnam M, Khalili A, Cortez L, Srinivasan M, Planel E Int J Nanomedicine. 2025; 20:1999-2019.

PMID: 39968061 PMC: 11834738. DOI: 10.2147/IJN.S494104.


Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases.

Tapia-Arellano A, Cabrera P, Cortes-Adasme E, Riveros A, Hassan N, Kogan M J Nanobiotechnology. 2024; 22(1):248.

PMID: 38741193 PMC: 11092257. DOI: 10.1186/s12951-024-02526-0.

References
1.
Vitet H, Brandt V, Saudou F . Traffic signaling: new functions of huntingtin and axonal transport in neurological disease. Curr Opin Neurobiol. 2020; 63:122-130. DOI: 10.1016/j.conb.2020.04.001. View

2.
Mohammadi F, Takalloo Z, Rahmani H, Khalili M, Khajeh K, Riazi G . Interplay of isoform 1N4R tau protein and amyloid-β peptide fragment 25-35 in reducing and non-reducing conditions. J Biochem. 2020; 169(1):119-134. DOI: 10.1093/jb/mvaa101. View

3.
Consoli G, Tosto R, Baglieri A, Petralia S, Campagna T, Di Natale G . Novel Peptide-Calix[4]arene Conjugate Inhibits Aβ Aggregation and Rescues Neurons from Aβ's Oligomers Cytotoxicity . ACS Chem Neurosci. 2021; 12(8):1449-1462. PMC: 9535895. DOI: 10.1021/acschemneuro.1c00117. View

4.
Sonawane S, Chidambaram H, Boral D, Gorantla N, Balmik A, Dangi A . EGCG impedes human Tau aggregation and interacts with Tau. Sci Rep. 2020; 10(1):12579. PMC: 7387440. DOI: 10.1038/s41598-020-69429-6. View

5.
Sonawane S, Ahmad A, Chinnathambi S . Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer's Disease. ACS Omega. 2019; 4(7):12833-12840. PMC: 6682074. DOI: 10.1021/acsomega.9b01411. View